Where is astrazeneca incorporated

Since the mids, Swedish pharmacists had been discussing the issue of domestic industrial production of pharmaceuticals in Sweden, as opposed to manual preparations by pharmacists. It was under the long-serving CEO, Borje Gabrielsson, who led the company between and , that Astra AB established its status as a leading Swedish pharmaceutical company. Astra introduced two important product families onto the Swedish market in penicillin and anaesthetics, initially in the form of Xylocaine.

The profits from these products funded the development of new drugs, such as gastroesophageal treatment Losec and cardiovascular treatment Aptin. However, it withdrew its neuropharmacological drug, Zelmid, which was an SSRI, due to concerns over side effects only a year after it was introduced in However, this new name has since caused confusion between Prilosec and Prozac.

The 90s also brought an increased perception that the pharmaceutical industry needed more international partnerships, and an increasing pressure on pharma companies as development costs of new drugs rose.

Responding to these pressures, Astra began to look for partners. British multinational pharma company Zeneca was formed by a demerger of the pharmaceuticals and agrochemicals businesses of Imperial Chemical Industries in The name Zeneca was invented by a branding consultancy who had been instructed by its chief executive, Sir David Barnes, to find a name which was memorable, had no associations with other companies, nor was offensive in any language.

In , Zeneca decided to sell its Zeneca Specialities division, which included activities in biocides, industrial colours, lifescience modules, performance and intermediate chemicals. It was this decision that fuelled many rumours that Zeneca was preparing to merge with another company. These rumours turned out to be true when the Astra and Zeneca merger was announced in December of the same year. On completion of the merger, Astra Shareholders held a In August , Nexium esomeprazole for the treatment of acid-related diseases, such as gastrooesophageal reflux disease GERD , was first launched in Sweden.

The same year, AZ also entered into its third collaboration agreement with Astex Therapeutics, this time to develop small-molecule protein kinase B PKB to further contribute in the fight against cancer. Convening health leaders to accelerate action on climate at COP We have projects in our pipeline.

View pipeline. Explore our technology. Explore all our science centres. Our sustainability ambition. You are now leaving AstraZeneca. Cancel Continue. Learn more about some of our key capabilities. If you are in the United States and would like additional information regarding AstraZeneca products, or you are a third party with an offer of services for AstraZeneca, you can contact the AstraZeneca Information Center by phone at Monday - Friday 8 a.

ET, excluding holidays. The Gaithersburg, MD campus, which is one of three global research and development centers along with Cambridge, UK and Gothenburg, Sweden designated to improving pipeline productivity and establishing the company as a global leader in biopharmaceutical innovation.

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca provides this link as a service to website visitors.

AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data.

Please refer to your approved national product label SmPC for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes. Cookie Policy This website uses cookies to help us give you the best experience when you visit.